Brewer and Grant are significatly different than Shoemaker in that they believe there is an ongoing colonization of mold in the body which causes a continuous supply of mycotoxin in the body. I am aware that many of Brewer's patients have improved significantly with his protocol, some dramatically. I will be seeing him later this week and I will know more then. Grant has published some results. Here they are:
M-1063
Neurological Disease After Mold Exposure, Immune Risks & Response to Biofilm-Focused Antifungal Therapy
J. F. Rini, MS -
.,
I. H. Grant, MD (Doctor of Medicine) - Clinical Assistant Professor, Department of Family and Community Medicine;
New York Med. Coll., Valhalla, NY.
Background: Stachybotrys (St) and
Aspergillus-Penicillium (Asp-Pen) biofilm products may cause symptoms (sxs) without invasion. Amphotericin B (Ampho), the only mold biofilm-eradicating antifungal, cannot cross tissues. Since mold toxins may cause neurological (neuro) sxs, upper-respiratory/GI biofilm-focused
antifungal therapy (Rx) was studied, correlating neuro sxs with immune risks, antibodies (AB’s), urine mycotoxins (MCT’s) and Rx response.
Methods: Monitored 25 patients with neuro sxs after proven mold exposure (11M,14F,age 27-91) for immune risks, specific AB’s, urine MCT’s and response to oral-nasal Ampho +/- systemic azoles or capsofungin.
Results: Debility paralled exposure intensity, impaired immunity, or multiple MCT’s.
Response to RX was striking with 21/23 (91%) unequivocally improved, most in 1-3 months. Penetration markers(adenopathy, nodules, calcification) required prolonged(>1 year)relapsing with interruptions.
Data
DOCUMENTED ENVIRONMENTAL
EXPOSURES
Aspergillus-Penicillium
21 (84%)
Stachybotrys
18 (72%)
SYMPTOMS
Severe 14
-7 Life-altering
-10 disabled)
Moderate
9
Mild
1
IMMUNITY RISK
23/25
(92%)
Innate Defects
(60%)
vitamin D deficient
15
Neutrophil Defects
(40%)
Protein deficient
10
Steroid Rx
6
Zinc deficient 5
TITERS
A.fumigatus
IgG + 15/15
5 (33%) elevated
S.chartarum
IgG + 12/18
2 elevated
IgA + 1/18
IgE undetectable 18/18 (100%)
MYCOTOXINS
(13 excreted multiple MCT’s)
Ochratoxin
19
Tricothecenes
(neurotoxic)
15
Aflatoxin
8
RX RESPONSE
21/23 (91%) unequivocally improved, many in 1-3 months
12 (48%) completed RX, 8 with residual disability
14 (67%) relapsed on interruption
- 13 improved on retreatment
Of 2 not treated & 3 discontinued:
-2 steadily deteriorated
- 3 were lost
Conclusion: Since
Stachybotrys &
Aspergillus-Penicillium exposure can result in neuro sxs that dramatically reverse with combined biofilm-focused/systemic antifungals, such sxs may result from
toxin mediated
fungal disease and should trigger mold exposure inquiry and screening for immune defects, quantitative mold IgG and mycotoxins. Controlled clinical antifungal trials are needed.